Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Instagram X-twitter Linkedin-in Youtube
GET IN TOUCH

Mana.bio

Mana.bio is an AI-based drug delivery startups focusing on gene therapy, including DNA and RNA-based therapeutics and vaccines
2021
Nov-50
11-50
California, United States

www.mana.bio

Drug Delivery and DevicesDrug Discovery and DevelopmentPersonalized Medicine Technologies
  • Drug Delivery and Devices
  • Drug Discovery and Development
  • Personalized Medicine Technologies
Innovation
Investment Funding
People
About
Products
Future Plan
M&A and Collabs
News

Innovation

Industry Problem

Nucleic-acid drugs can be difficult to deliver safely and selectively to tissues beyond the liver.

R&D Focus

AI-designed lipid nanoparticles and tissue-targeted nucleic-acid delivery.

Innovative Solution

An AI and experimental platform designs lipid nanoparticle formulations for DNA, RNA and gene-editing payloads with tissue-specific delivery goals.

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

$24.5M

Last Funding Amount

$19.5M

Last Funding Date

10-12-2023

Startup Stage

Early Stage

Lead Investors

Andreessen Horowitz, Base4 Capital, Technion Israel Institute of Technology, LionBird, NFX

People

Founders

  • Yogev Debbi
  • Roy Nevo
  • Avi Schroeder
  • Kira Radinsky

CEO

  • Yogev Debbi

About

Mana.bio is an AI-based drug delivery startups focusing on gene therapy, including DNA and RNA-based therapeutics and vaccines

Products

Product

Mana LNP discovery platform and Mina AI agent for nucleic-acid delivery design.

Star Product

Mana LNP platform, because it is the core engine used to develop tissue-targeted delivery systems.

Demo Product or Complete Product?

Preclinical platform and partner-development stage.

Future Plan

Market Expansion

Expanding partnerships across RNA therapeutics, gene editing and vaccines.

Investment Funding

$19.5 million oversubscribed seed round announced to advance the platform and partnerships.

M&A and Collabs

Collab

Sheba Medical Center ARC: translational collaboration in nucleic-acid therapeutics.

Collab

Biopharma partners: design and validation of tissue-targeted lipid nanoparticles.

Something missing or incorrect on this page? Help us enrich this information

Claim Now and Contribute